Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 4/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623484 | 0.99 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL4621677 | 0.94 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8576778 | 0.94 | ADORA1 (0.88) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8578131 | 0.94 | ADORA1 (0.88) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8356923 | 0.92 | ADORA1 (0.85) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL14903087 | 0.92 | ADORA1 (0.85) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8578935 | 0.92 | ADORA1 (0.84) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8509843 | 0.92 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8352479 | 0.92 | ADORA1 (0.84) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8576452 | 0.92 | ADORA1 (0.84) | ADORA1ADORA2AADORA2BADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648778-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | National Health Research Institutes (TW) | 2025-11-19 | — | — | EP | claimed |
| CN-119139472-A | Application of adenosine signal blocker in preparing medicament for treating amblyopia and improving vision plasticity | 温州医科大学附属眼视光医院 | 2024-12-17 | — | — | CN | claimed |
| CN-118892547-A | Judging application of peripheral neuropathic pain central treatment | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 2024-11-05 | — | — | CN | claimed |
| WO-2024151651-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2024-07-18 | — | — | WO | claimed |
| CN-117321080-A | Combination therapy using anti-CD 38 antibodies and PARP or adenosine receptor inhibitors | 詹森生物科技公司 | 2023-12-29 | — | — | CN | claimed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | JANSSEN BIOTECH, INC. | 2022-09-01 | — | — | US | claimed |
| WO-2022175920-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| EP-3876871-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | The Regents of the University of California (US) | 2021-09-15 | — | — | EP | claimed |
| US-20200182859-A1 | HDAC1/2 ACTIVATOR FOR PROMOTING AND/OR ACCELERATING MYELINATION AND/OR REMYELINATION | UNIVERSITE DE FRIBOURG (CH) | 2020-06-11 | — | — | US | claimed |
| US-5629298-A | INCREASING CONTRACTILE PERFORMANCE, ADENOSINE TRANSPORT INHIBITORS USED AS POTENTIATORS | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1997-05-13 | — | — | US | claimed |
| EP-0755254-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-01-29 | — | — | EP | claimed |
| WO-1996028163-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1996-09-19 | — | — | WO | claimed |
| WO-1995026728-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-10-12 | — | — | WO | claimed |
| US-5424297-A | Adenosine dextran conjugates | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1995-06-13 | — | — | US | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| US-5366977-A | Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-11-22 | — | — | US | claimed |
| WO-1993021949-A1 | IMMUNOLOGICAL DETECTION AND QUANTIFICATION OF 8-(CYCLOALKYL OR AROMATIC) SUBSTITUTED-1,3-DIPROPYLXANTHINES | VANDERBILT UNIVERSITY (US) | 1993-11-11 | — | — | WO | claimed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | CD38, PARP1, PARP11 | ADORA1 25/4885ADORA2A 16/4885ADORA2B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.